You searched for "intracameral"

589 results found

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

The management of retinal vein occlusions: a summary

Retinal vein occlusions (RVO) are the most common cause of visual loss from retinal vascular disease second to diabetic retinopathy. Vision is lost due to ischaemia, macular oedema and / or haemorrhage which ultimately effects a patient’s quality of life...

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents

In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...

Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment

A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. Funded by...

Moorfields implementing a non-medical intravitreal injection service

This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services. With an increasing demand in treatment for people with eye conditions such as...

Moorfields: Implementing a non-medical intravitreal injection service

This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services. With an increasing demand in treatment for people with eye conditions such as...

Moorfields: Implementing a non-medical intravitreal injection service Nov

This highly sought after intravitreal injection course has had a national and global impact by enabling numerous institutions to establish their own non-medical delivered IVT injection services.

Intravitreal aflibercept for retinal angiomatous proliferation (RAP)

In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection

In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...

Insights in resistant diabetic macular oedema

This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...